Basic Information
RELITREXED POWDER FOR SOLUTION FOR INFUSION 100MG/VIAL
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN16521P
June 24, 2022
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XL01BA04
Company Information
WELLCHEM PHARMACEUTICALS PTE LTD
WELLCHEM PHARMACEUTICALS PTE LTD
Active Ingredients
Strength: 100mg/vial
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Breast-feeding (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Concomitant yellow fever vaccine (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Malignant pleural mesothelioma (MPM) _ReliTrexed_ ® in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma or who otherwise not candidates for curative surgery. Non-small cell lung cancer (NSCLC) (see sections 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_): _ReliTrexed_ ® in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-squamous NSCLC. _ReliTrexed_ ® in combination with pembrolizumab and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. _ReliTrexed_ ® is indicated as monotherapy for the maintenance treatment of locally advance or metastatic non-squamous NSCLC in patients whose disease has not progressed immediately following first-line treatment with platinum-based chemotherapy. _ReliTrexed_ ® is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-squamous NSCLC.